Seminars in Oncology
Volume 33 , Pages 2-5 , December 2006

Biomarkers of Response to Preoperative Chemoradiation in Esophageal Cancers

  • Rajyalakshmi Luthra

      Affiliations

    • Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationAddress reprint requests to Rajyalakshmi Luthra, PhD, Division of Pathology and Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, 8515 Fannin St, NAO1.091, Houston, TX 77054
    • ,
  • Madan G. Luthra

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Julie Izzo

      Affiliations

    • Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Tsung-Teh Wu

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Enrique Lopez-Alvarez

      Affiliations

    • Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Usha Malhotra

      Affiliations

    • Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • In Seon Choi

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Li Zhang

      Affiliations

    • Department of Biostatistics & Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Jaffer A. Ajani

      Affiliations

    • Department of GI Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev. 2003;29:525–532
  3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–2252
  4. Pera M. Recent changes in the epidemiology of esophageal cancer. Surg Oncol. 2001;10:81–90
  5. Bollschweiler E, Wolfgarten E, Gutschow C, et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 2001;92:549–555
  6. Wild CP, Hardie LJ. Reflux, Barrett’s oesophagus and adenocarcinoma: Burning questions. Nat Rev Cancer. 2003;3:676–684
  7. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett’s esophagus (A prevalent, occult complication of gastroesophageal reflux disease). Gastroenterology. 1987;92:118–124
  8. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett’s esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg. 2003;27:999–1008
  9. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus. N Engl J Med. 1985;313:857–859
  10. Robertson CS, Mayberry JF, Nicholson DA, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett’s oesophagus. Br J Surg. 1988;75:760–763
  11. Hameeteman W, Tytgat GN, Houthoff HJ, et al. Barrett’s esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249–1256
  12. Oberg S, Wenner J, Johansson J, et al. Barrett’s esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg. 2005;242:49–54
  13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  14. Chaves P, Pereira AD, Pinto A, et al. p53 protein immunoexpression in esophageal squamous cell carcinoma and adjacent epithelium. J Surg Oncol. 1997;65:3–9
  15. Casson AG, Manolopoulos B, Troster M, et al. Clinical implications of p53 gene mutation in the progression of Barrett’s epithelium to invasive esophageal cancer. Am J Surg. 1994;167:52–57
  16. Yokota J, Yamamoto T, Toyoshima K, et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet. 1986;1:765–767
  17. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347–1355
  18. Rohatgi PR, Swisher SG, Correa AM, et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006;106:552–558
  19. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330–4337
  20. Darnton SJ, Archer VR, Stocken DD, et al. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol. 2003;21:4009–4015
  21. Lu J, Liu Z, Xiong M, et al. Gene expression profile changes in initiation and progression of squamous cell carcinoma of esophagus. Int J Cancer. 2001;91:288–294
  22. Xu Y, Selaru FM, Yin J, et al. Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett’s esophagus and esophageal cancer. Cancer Res. 2002;62:3493–3497
  23. Xu SH, Qian LJ, Mou HZ, et al. Difference of gene expression profiles between esophageal carcinoma and its pericancerous epithelium by gene chip. World J Gastroenterol. 2003;9:417–422
  24. Hourihan RN, O’Sullivan GC, Morgan JG. Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res. 2003;23:161–165
  25. Zhou J, Zhao LQ, Xiong MM, et al. Gene expression profiles at different stages of human esophageal squamous cell carcinoma. World J Gastroenterol. 2003;9:9–15
  26. Ishibashi Y, Hanyu N, Nakada K, et al. Profiling gene expression ratios of paired cancerous and normal tissue predicts relapse of esophageal squamous cell carcinoma. Cancer Res. 2003;63:5159–5164
  27. Dahlberg PS, Ferrin LF, Grindle SM, et al. Gene expression profiles in esophageal adenocarcinoma. Ann Thorac Surg. 2004;77:1008–1015
  28. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett’s esophagus. Cancer Res. 2004;64:1561–1569
  29. Luo A, Kong J, Hu G, et al. Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene. 2004;23:1291–1299
  30. Kazemi-Noureini S, Colonna-Romano S, Ziaee AA, et al. Differential gene expression between squamous cell carcinoma of esophageus and its normal epithelium; altered pattern of mal, akr1c2, and rab11a expression. World J Gastroenterol. 2004;10:1716–1721
  31. Brabender J, Marjoram P, Salonga D, et al. A multigene expression panel for the molecular diagnosis of Barrett’s esophagus and Barrett’s adenocarcinoma of the esophagus. Oncogene. 2004;23:4780–4788
  32. Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: Association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006;24:259–267
  33. The University of Texas M. D. Anderson Cancer Center: Microarray Core Facility. Available at: http://www.mdanderson.org/departments/dnamicroarray) (Accessed June 27, 2006)
  34. Kimchi ET, Posner MC, Park JO, et al. Progression of Barrett’s metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 2005;65:3146–3154
  35. Ihrie RA, Reczek E, Horner JS, et al. Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol. 2003;13:1985–1990
  36. Nagy N, Brenner C, Markadieu N, et al. S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Lab Invest. 2001;81:599–612
  37. Ji J, Zhao L, Wang X, et al. Differential expression of S100 gene family in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2004;130:480–486
  38. Kimos MC, Wang S, Borkowski A, et al. Esophagin and proliferating cell nuclear antigen (PCNA) are biomarkers of human esophageal neoplastic progression. Int J Cancer. 2004;111:415–417
  39. Izzo J, Malhotra U, Wu TT, et al. Association of activated transcription factor NF-kappaB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006;24:748–754
  40. Abdel-Latif MM, O’Riordan J, Windle HJ, et al. NF-kappaB activation in esophageal adenocarcinoma: Relationship to Barrett’s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239:491–500

PII: S0093-7754(06)00381-2

doi: 10.1053/j.seminoncol.2006.10.004

Seminars in Oncology
Volume 33 , Pages 2-5 , December 2006

Article Tools

* Image Usage & Resolution